LK-3

N/A

Report date: 2025/06/11 10:19:28

Base Information

Drug NameLK-3
Drug Alias NameS100 calcium binding protein P inhibitor (Lykera Biomed SA)anti-S100P monocloanl antibody (Lykera Biomed SA)3F8 (Lykera)2H8LK-3 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionS100 Calcium Binding Protein P inhibitorsImmunomodulators
TargetsS100 Calcium Binding Protein P
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLykera Biomed Sa
China Registration ClassN/A

Develop Information

Active CompaniesLykera Biomed Sa
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A